Receptor tyrosine kinase inhibitors for treatment of protein kinase modulation-responsive disease or disorder

Abstract

Ephrin type receptor tyrosine kinase inhibitors, also known as Eph tyrosine kinase receptor inhibitors, for treating cancer, an inflammatory disease, an autoimmune disease, or a degenerative disease characterized at least in part by the abnormal activity or expression of the Eph receptor tyrosine kinase. The inhibitors are particularly useful for treating certain cancers.

Dependencies are inferred from the claim text.